| Range: | 11.4-27.2 | Vol Avg: | 1530379 | Last Div: | 0 | Changes: | 0.58 |
| Beta: | 1.11 | Cap: | 1.60B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Jun 18 2014 | Empoloyees: | 94 | ||
| CUSIP: | 92790C104 | CIK: | 0001590750 | ISIN: | US92790C1045 | Country: | US |
| CEO: | Mr. Stephen F. Mahoney J.D., MBA | Website: | https://www.viridiantherapeutics.com | ||||
VRDN 20.20 Stock Price Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Stock Details
Positive 0.50
Viridian Therapeutics' Superior Prospects Make It A Buy
Viridian Therapeutics, Inc.'s VRDN-001, now Veligrotug, shows promising phase 3 data in Th...
seekingalpha.com·Wed Oct 23 2024
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow